盘龙药业(002864) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 225,625,209.86, representing a 13.48% increase compared to CNY 198,828,511.27 in the same period last year[4] - Net profit attributable to shareholders was CNY 21,561,607.43, up 7.37% from CNY 20,081,539.34 year-on-year[4] - Total operating revenue for Q1 2023 reached CNY 225,625,209.86, an increase of 13.5% compared to CNY 198,828,511.27 in Q1 2022[24] - Net profit for Q1 2023 was CNY 21,812,305.64, representing an increase of 7.4% from CNY 20,311,464.87 in Q1 2022[25] - The total comprehensive income for the period was CNY 21,812,305.64, compared to CNY 20,311,464.87 in the previous period, reflecting an increase of approximately 7.4%[26] - The company reported a basic earnings per share of CNY 0.24, up from CNY 0.23 in the previous period, representing an increase of about 4.3%[26] Cash Flow - The net cash flow from operating activities significantly decreased by 96.14%, amounting to CNY 1,522,659.83 compared to CNY 39,416,073.24 in the previous year[4] - The net cash flow from financing activities decreased by 102.93% to CNY -10,705,969.23, primarily due to the previous period's fundraising from convertible bonds[9] - The total cash inflow from financing activities was CNY 100,213,637.50, down from CNY 414,450,344.29 in the previous period, indicating a decrease of approximately 75.8%[29] - The net cash flow from financing activities showed a net outflow of CNY 10,705,969.23, contrasting with a net inflow of CNY 365,916,650.78 in the previous period[29] - The cash and cash equivalents at the end of Q1 2023 amounted to RMB 796.26 million, down from RMB 823.44 million at the beginning of the year[21] - The cash and cash equivalents at the end of the period were CNY 796,263,057.99, a decrease from CNY 805,044,185.42 in the previous period[29] Assets and Liabilities - The company's total assets decreased by 0.86% to CNY 1,914,264,568.03 from CNY 1,930,786,964.46 at the end of the previous year[4] - The total liabilities decreased to CNY 711,604,108.49 from CNY 983,183,297.68, indicating a reduction of 27.6%[23] - The equity attributable to shareholders increased by 27.41% to CNY 1,184,456,817.61 from CNY 929,650,723.07 at the end of the previous year[4] - The equity attributable to shareholders increased to CNY 1,184,456,817.61 from CNY 929,650,723.07, reflecting a growth of 27.4%[23] Operating Costs and Expenses - The company reported a 33.41% increase in operating costs, totaling CNY 114,243,787.63, primarily due to increased sales volume and changes in product sales structure[8] - Total operating costs amounted to CNY 200,170,026.24, up from CNY 172,988,132.13, reflecting a year-over-year increase of 15.7%[25] - Research and development expenses rose by 60.70% to CNY 3,280,480.41, reflecting increased investment in R&D[8] - Research and development expenses for the quarter were CNY 3,280,480.41, up from CNY 2,041,330.57, marking a significant increase of 60.9%[25] - The company paid CNY 21,712,469.37 to employees, which increased from CNY 19,478,731.73 in the previous period, reflecting an increase of about 11.3%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,594[10] - The largest shareholder, Xie Xiaolin, holds 38.37% of the shares, amounting to 37,189,932 shares[10] Convertible Bonds - The company issued 2,760,000 convertible bonds with a total issuance amount of RMB 276 million, netting RMB 271.98 million after expenses[13] - As of March 29, 2023, there were 49,743 unconverted "Panlong Convertible Bonds" redeemed at a price of RMB 100.05 per bond, totaling RMB 4.98 million[14] - The company plans to issue A-shares to specific investors, with the proposal approved by the shareholders' meeting[16] Credit and Inventory - The company experienced a 441.62% increase in credit impairment losses, amounting to CNY -1,815,375.48, attributed to an increase in accounts receivable[9] - The company's accounts receivable rose to CNY 460,578,034.96, compared to CNY 443,556,640.27 in the previous quarter, showing an increase of 3.2%[23] - Inventory levels increased to CNY 96,221,666.87 from CNY 94,628,102.72, reflecting a growth of 1.7%[23]